JP2021501783A - ペプチド抗生物質 - Google Patents

ペプチド抗生物質 Download PDF

Info

Publication number
JP2021501783A
JP2021501783A JP2020524807A JP2020524807A JP2021501783A JP 2021501783 A JP2021501783 A JP 2021501783A JP 2020524807 A JP2020524807 A JP 2020524807A JP 2020524807 A JP2020524807 A JP 2020524807A JP 2021501783 A JP2021501783 A JP 2021501783A
Authority
JP
Japan
Prior art keywords
group
substituted
alkyl
hydrogen
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020524807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501783A5 (enExample
Inventor
マシュー クーパー
マシュー クーパー
マーク ブラスコビッチ
マーク ブラスコビッチ
アレジャンドラ ガラードゥ−ゴドイ
アレジャンドラ ガラードゥ−ゴドイ
カール ハンスフォード
カール ハンスフォード
アリシャ エリオット
アリシャ エリオット
クレイグ マルドゥーン
クレイグ マルドゥーン
バーンド ベッカー
バーンド ベッカー
Original Assignee
ザ ユニバーシティー オブ クイーンズランド
ザ ユニバーシティー オブ クイーンズランド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017904465A external-priority patent/AU2017904465A0/en
Application filed by ザ ユニバーシティー オブ クイーンズランド, ザ ユニバーシティー オブ クイーンズランド filed Critical ザ ユニバーシティー オブ クイーンズランド
Publication of JP2021501783A publication Critical patent/JP2021501783A/ja
Publication of JP2021501783A5 publication Critical patent/JP2021501783A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2020524807A 2017-11-02 2018-11-02 ペプチド抗生物質 Pending JP2021501783A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017904465A AU2017904465A0 (en) 2017-11-02 Peptide antibiotics
AU2017904465 2017-11-02
PCT/AU2018/051194 WO2019084628A1 (en) 2017-11-02 2018-11-02 Peptide antibiotics

Publications (2)

Publication Number Publication Date
JP2021501783A true JP2021501783A (ja) 2021-01-21
JP2021501783A5 JP2021501783A5 (enExample) 2021-12-16

Family

ID=66331139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020524807A Pending JP2021501783A (ja) 2017-11-02 2018-11-02 ペプチド抗生物質

Country Status (6)

Country Link
US (1) US11279733B2 (enExample)
EP (1) EP3704135A4 (enExample)
JP (1) JP2021501783A (enExample)
CN (1) CN111527100A (enExample)
AU (1) AU2018359018B2 (enExample)
WO (1) WO2019084628A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4161481A4 (en) * 2020-06-05 2024-09-25 The Rockefeller University NATURAL BIOINFORMATIC SYNTHETIC ANTIBACTERIAL PRODUCTS AND THEIR USES
EP4330269A4 (en) * 2021-04-27 2025-07-09 Univ Rockefeller MACOLACINS AND METHODS OF USE THEREOF

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57171925A (en) * 1981-04-03 1982-10-22 Bristol Mayers Kenkyusho Kk Antibiotic compound
JPS59134764A (ja) * 1982-10-06 1984-08-02 ヴア−ラ・マルチ 抗菌的治療に有用な化合物、グラム陰性菌の感作方法及びそのための組成物
JP2008505858A (ja) * 2004-07-01 2008-02-28 バイオソース・ファーム・インコーポレイテッド ペプチド抗生物質およびその製造方法
JP2010500331A (ja) * 2006-08-11 2010-01-07 ノーザン アンチバイオティクス オイ ポリミキシン誘導体およびその使用
US20140162937A1 (en) * 2008-02-08 2014-06-12 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
JP2015145399A (ja) * 2008-02-08 2015-08-13 ノーザン アンチバイオティクス オイ 短鎖脂肪酸の尾部を有するポリミキシン誘導体およびその使用
JP2017510570A (ja) * 2014-03-11 2017-04-13 ニュー・ファーマ・ライセンス・ホールディングス・リミテッド 異なった抗生物質と一緒の組合せ療法におけるポリミキシン誘導体及びその使用
JP2017512818A (ja) * 2014-04-01 2017-05-25 モナシュ、ユニバーシティＭｏｎａｓｈ Ｕｎｉｖｅｒｓｉｔｙ 抗菌性化合物としてのポリミキシン誘導体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880994A (en) 1972-12-06 1975-04-29 Bristol Myers Co Antibiotic BU-1880
JPS5025795A (enExample) 1973-07-10 1975-03-18
CA2047033A1 (en) * 1990-07-19 1992-01-20 Elizabeth E. Sugg Cyclic hiv principal neutralizing determinant peptides
WO2002055543A2 (en) * 2001-01-16 2002-07-18 Univ Ramot Hybrid peptides for treatment of bacteremia and septicemia
WO2010130007A1 (en) 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
ES2374779B1 (es) 2010-03-10 2012-12-27 Universidad De Barcelona Compuestos péptidicos útiles como agentes antibacterianos.
WO2012168820A1 (en) 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
KR20140091724A (ko) * 2011-11-18 2014-07-22 노박타 바이오시스템스 리미티드 폴리믹신 유도체
BR112015029309A2 (pt) 2013-05-22 2017-07-25 New Pharma Licence Holdings Ltd derivados de polimixina e seu uso em terapia de combinação junto com antibióticos diferentes
CN107108699A (zh) * 2014-11-26 2017-08-29 新药物许可控股有限公司 化合物
US9771394B2 (en) 2014-12-16 2017-09-26 Micurx Pharmaceuticals, Inc. Antimicrobial polymyxins for treatment of bacterial infections
JP6873043B2 (ja) 2015-03-23 2021-05-19 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ ベータ−ヘアピンペプチド模倣体
CA3000032A1 (en) 2015-09-29 2017-04-06 Monash University Antimicrobial polymyxin derivative compounds
WO2017189868A1 (en) * 2016-04-27 2017-11-02 Spero Opco Serine replacement polymyxin analogues useful as antibiotic potentiators

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57171925A (en) * 1981-04-03 1982-10-22 Bristol Mayers Kenkyusho Kk Antibiotic compound
JPS59134764A (ja) * 1982-10-06 1984-08-02 ヴア−ラ・マルチ 抗菌的治療に有用な化合物、グラム陰性菌の感作方法及びそのための組成物
JP2008505858A (ja) * 2004-07-01 2008-02-28 バイオソース・ファーム・インコーポレイテッド ペプチド抗生物質およびその製造方法
JP2010500331A (ja) * 2006-08-11 2010-01-07 ノーザン アンチバイオティクス オイ ポリミキシン誘導体およびその使用
US20140162937A1 (en) * 2008-02-08 2014-06-12 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
JP2015145399A (ja) * 2008-02-08 2015-08-13 ノーザン アンチバイオティクス オイ 短鎖脂肪酸の尾部を有するポリミキシン誘導体およびその使用
JP2017510570A (ja) * 2014-03-11 2017-04-13 ニュー・ファーマ・ライセンス・ホールディングス・リミテッド 異なった抗生物質と一緒の組合せ療法におけるポリミキシン誘導体及びその使用
JP2017512818A (ja) * 2014-04-01 2017-05-25 モナシュ、ユニバーシティＭｏｎａｓｈ Ｕｎｉｖｅｒｓｉｔｙ 抗菌性化合物としてのポリミキシン誘導体

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOCHEMISTRY, 1980, VOL.19, PP.3307-3314, JPN6022040999, ISSN: 0005043403 *
BIOORG. MED. CHEM. LETT., 2017.04.12, VOL.27, PP.2407-2409, JPN6022040998, ISSN: 0005043402 *
CHEM. PHARM. BULL., 2011, VOL.59, NO.5, PP.597-602, JPN6022041001, ISSN: 0004885714 *
CURR. OPIN. MICROBIOL., 2010, VOL.13, PP.574-581, JPN6022041000, ISSN: 0004885713 *
J. ANTIBIOTICS, 1976, VOL.29, NO.12, PP.1339-1340, JPN6022041002, ISSN: 0004885715 *

Also Published As

Publication number Publication date
EP3704135A1 (en) 2020-09-09
EP3704135A4 (en) 2022-04-27
AU2018359018A1 (en) 2020-05-14
AU2018359018B2 (en) 2022-11-24
US11279733B2 (en) 2022-03-22
CN111527100A (zh) 2020-08-11
US20200361994A1 (en) 2020-11-19
WO2019084628A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
JP7117021B2 (ja) 抗菌性化合物としてのポリミキシン誘導体
EP2331501B1 (en) Small molecule inhibitors of n-terminus activation of the androgen receptor
CN114051496B (zh) 将联苯基引入新型氨基烷酸的衍生物化合物及包含其的抗真菌药学组合物
WO2012051663A1 (en) Antimicrobial compounds
WO2017218922A2 (en) Compositions and methods for the treatment of bacterial infections
JP2021501783A (ja) ペプチド抗生物質
KR20180024002A (ko) 신규한 바이사이클릭 리포란티펩티드, 제조 및 항균제로서의 용도
CA2954653C (en) N-(hydrophobe-substituted)vancosaminyl [.psi.[c(=nh)nh]tpg4]vancomycin and [.psi.[ch2nh]tpg4]vancomycin
US20250074945A1 (en) Antibacterial cyclopeptides targeting acinetobacter and other gram-negative pathogens
KR20250037534A (ko) 리포올리고우레아, 약학 조성물, 및 의약으로서 사용하기 위한 리포올리고우레아
EP4132945A2 (en) Antibacterial lipopeptides, pharmaceutical composition and cosmetic composition comprising them, and uses thereof
WO2020079001A1 (en) Compounds for use in the treatment of bacterial infections
PL226349B1 (pl) Pentapeptydy zawierające 3-[2-(2-chinolilo)benzoksazol-5-ylo] alaninę, kompozycja farmaceutyczna oraz ich zastosowanie
HK1153198B (en) Small molecule inhibitors of n-terminus activation of the androgen receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200629

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211102

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230424